|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0024623,
umls-concept:C0030705,
umls-concept:C0030956,
umls-concept:C0042196,
umls-concept:C0178539,
umls-concept:C0205470,
umls-concept:C0220825,
umls-concept:C0871261,
umls-concept:C1527178,
umls-concept:C1704632,
umls-concept:C1705938,
umls-concept:C1706817,
umls-concept:C2347662,
umls-concept:C2911692
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2003-9-11
|
|
pubmed:abstractText |
There is no standard treatment modality for advanced gastric cancer (GC) at the present time. To develop a new treatment modality, we investigated the immunological responses of advanced GC patients (n = 13, 9 non-scirrhous and 4 scirrhous types) vaccinated with peptides to a regimen under which pre-vaccination peripheral blood mononuclear cells (PBMCs) were screened for their reactivity in vitro to each of 14 peptides on HLA-A24 or 16 peptides on -A2 allele, then only the reactive peptides (maximum: 4) were administered in vivo. This regimen was generally well tolerated, although grade I levels of fever and local skin reactions were observed in several patients. Delayed-type hypersensitivity (DTH) to the vaccinated peptides was observed in 4 patients. Increased cellular and humoral immune responses to the vaccinated peptides were observed in post-vaccination PBMCs from 4 of 8 patients and in post-vaccination sera of 8 of 10 patients tested, respectively. Prolonged survival was observed in patients showing cellular and humoral immune responses to the vaccinated peptides in the post-vaccination samples, including all 4 patients with the scirrhous type. These results encourage further development of peptide-based immunotherapy for GC patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1347-9032
|
|
pubmed:author |
pubmed-author:AkasakaYoshinobuY,
pubmed-author:ItohKyogoK,
pubmed-author:KatagiriKazukoK,
pubmed-author:KondoMasaoM,
pubmed-author:MaedaYoshiakiY,
pubmed-author:MatsuiKanaeK,
pubmed-author:MineTakashiT,
pubmed-author:OkadaShioriS,
pubmed-author:SatoMikaM,
pubmed-author:SatoYujiY,
pubmed-author:ShinoharaToshikiT,
pubmed-author:ShomuraHirokiH,
pubmed-author:TakahashiShusakuS,
pubmed-author:TodoSatoruS,
pubmed-author:UneYoshieY,
pubmed-author:YamadaAkiraA,
pubmed-author:YamanaHideakiH
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
94
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
802-8
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:12967479-Adenocarcinoma,
pubmed-meshheading:12967479-Aged,
pubmed-meshheading:12967479-Cancer Vaccines,
pubmed-meshheading:12967479-Cytotoxicity, Immunologic,
pubmed-meshheading:12967479-Female,
pubmed-meshheading:12967479-HLA-A Antigens,
pubmed-meshheading:12967479-HLA-A2 Antigen,
pubmed-meshheading:12967479-HLA-A24 Antigen,
pubmed-meshheading:12967479-Humans,
pubmed-meshheading:12967479-Immunity, Cellular,
pubmed-meshheading:12967479-Lymphatic Metastasis,
pubmed-meshheading:12967479-Male,
pubmed-meshheading:12967479-Middle Aged,
pubmed-meshheading:12967479-Neoplasm Recurrence, Local,
pubmed-meshheading:12967479-Peptide Fragments,
pubmed-meshheading:12967479-Skin Tests,
pubmed-meshheading:12967479-Stomach Neoplasms,
pubmed-meshheading:12967479-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:12967479-Treatment Outcome,
pubmed-meshheading:12967479-Vaccination
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide.
|
|
pubmed:affiliation |
First Department of Surgery, Hokkaido University School of Medicine, N15 W7 Sapporo, Hokkaido 060-8638, Japan.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
